Patient characteristics
| . | MM1 . | MM2 . | MM3 . | MM4 . |
|---|---|---|---|---|
| Baseline characteristics | ||||
| Age at diagnosis | 37 | 50 | 47 | 56 |
| Age at CAR-T therapy | 40 | 55 | 51 | 61 |
| Sex | Male | Male | Male | Female |
| MM subtype | IgA κ | IgG κ | IgG λ | κ light chain |
| ISS stage | 2 | 3 | 3 | 3 |
| Cytogenetics | HR | SR | HR | SR |
| Previous ASCT | Yes | Yes | Yes | Yes |
| Penta-refractory disease | Yes | Yes | Yes | Yes |
| BM-PC before ide-cel, % | <5 | 10 | 80 | 2 |
| Outcome on nivolumab-based salvage therapy | ||||
| PFS after first CAR-T, mo | 13.6 | 11.7 | 8.8 | 3.0 |
| Best response to first CAR-T | CR | CR | VGPR | VGPR |
| PFS after second CAR-T, mo | 1.4 | 1.3 | 5.1 | Not infused |
| Best response to second CAR-T | PD | PD | PR | Not infused |
| Salvage regimen | Nivo-Rd | Nivo-Pd | Nivo-Pd | Nivo-Rd |
| TTNT, mo | 0.4 | 3.4 | 8.0 | 3.6 |
| Best response | PD | PR | SD | PD |
| Subsequent therapy | KC(d) | DRd | Tec | DVd |
| . | MM1 . | MM2 . | MM3 . | MM4 . |
|---|---|---|---|---|
| Baseline characteristics | ||||
| Age at diagnosis | 37 | 50 | 47 | 56 |
| Age at CAR-T therapy | 40 | 55 | 51 | 61 |
| Sex | Male | Male | Male | Female |
| MM subtype | IgA κ | IgG κ | IgG λ | κ light chain |
| ISS stage | 2 | 3 | 3 | 3 |
| Cytogenetics | HR | SR | HR | SR |
| Previous ASCT | Yes | Yes | Yes | Yes |
| Penta-refractory disease | Yes | Yes | Yes | Yes |
| BM-PC before ide-cel, % | <5 | 10 | 80 | 2 |
| Outcome on nivolumab-based salvage therapy | ||||
| PFS after first CAR-T, mo | 13.6 | 11.7 | 8.8 | 3.0 |
| Best response to first CAR-T | CR | CR | VGPR | VGPR |
| PFS after second CAR-T, mo | 1.4 | 1.3 | 5.1 | Not infused |
| Best response to second CAR-T | PD | PD | PR | Not infused |
| Salvage regimen | Nivo-Rd | Nivo-Pd | Nivo-Pd | Nivo-Rd |
| TTNT, mo | 0.4 | 3.4 | 8.0 | 3.6 |
| Best response | PD | PR | SD | PD |
| Subsequent therapy | KC(d) | DRd | Tec | DVd |
ASCT, autologous stem cell transplantation; BM-PC, bone marrow plasma cell; DRd, daratumumab-lenalidomide-dexamethasone; DVd, daratumumab-bortezomib-dexamethasone; HR, cytogenetic high risk (defined as del17p, t(4;14), t(14;16), ampl1q); ISS, International Staging System; KC(d), carfilzomib-cyclophosphamide(-dexamethasone); IgA/G, immunoglobulin A/G; Nivo, nivolumab; Pd, pomalidomide-dexamethasone; PD, progressive disease; PR, partial response; Rd, lenalidomide-dexamethasone; SD, stable disease; SR, cytogenetic standard risk (all aberrations except from HR); Tec, teclistamab; TTNT, time-to-next treatment; VGPR, very good partial response.